Analyst Price Targets — MNKD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 13, 2026 2:44 pm | — | Mizuho Securities | $8.00 | $2.58 | TheFly | MannKind price target lowered to $8 from $10 at Mizuho |
| April 8, 2026 12:27 pm | — | Truist Financial | $6.00 | $2.61 | TheFly | MannKind price target lowered to $6 from $7 at Truist |
| November 24, 2025 12:24 pm | — | Truist Financial | $9.00 | $5.03 | TheFly | MannKind initiated with a Buy at Truist |
| September 2, 2025 1:42 pm | — | H.C. Wainwright | $11.00 | $5.74 | TheFly | MannKind price target raised to $11 from $9 at H.C. Wainwright |
| August 26, 2025 11:28 am | Douglas Miehm | RBC Capital | $8.00 | $4.00 | TheFly | MannKind price target raised to $8 from $7 at RBC Capital |
| August 25, 2025 4:22 pm | — | H.C. Wainwright | $9.00 | $3.90 | TheFly | H.C. Wainwright positive on MannKind deal for scPharmaceuticals |
| August 28, 2024 7:55 am | Steven Lichtman | Oppenheimer | $12.00 | $5.38 | TheFly | MannKind price target raised to $12 from $10 at Oppenheimer |
| October 10, 2023 12:57 pm | Andreas Argyrides | Wedbush | $10.00 | $4.23 | Benzinga | MannKind Analyst Turns Bullish, Says 'Don't Call It Comeback' |
Latest News for MNKD
MannKind Corporation (NASDAQ: MNKD - Get Free Report) saw a large growth in short interest in March. As of March 31st, there was short interest totaling 29,464,200 shares, a growth of 29.8% from the March 15th total of 22,701,389 shares. Approximately 9.8% of the company's stock are short sold. Based on an average daily volume of
MannKind Corporation (NASDAQ: MNKD - Get Free Report) gapped up prior to trading on Wednesday after an insider bought additional shares in the company. The stock had previously closed at $2.61, but opened at $2.81. MannKind shares last traded at $2.7950, with a volume of 2,318,445 shares. Specifically, CEO Michael Castagna bought 100,000 shares of the
MannKind Corporation (MNKD) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Presentations highlight real‑world dosing and titration patterns in youth, and post‑prandial glucose management strategies using inhaled insulin in both adults and youth with T1D Data to be featured across oral and poster sessions at the Advanced Technologies & Treatments for Diabetes Conference (ATTD) PDUFA target action date for Afrezza in children and adolescents living with type 1 or type 2 diabetes set for May…
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced the settlement of the remaining $36.3 million aggregate principal amount of 2.50% convertible senior notes, all of which were tendered for conversion prior to the maturity date of March 1, 2026. The settlement was made on March 4, 2026, with $35.5 million in cash and 569,023 shares of…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MNKD.
U.S. House Trading
No House trades found for MNKD.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.